▁Introduction 7.8203125
: 1.9072265625
<0x0A> 6.51953125
M 4.66796875
el 4.4921875
an 2.73828125
oma 0.33837890625
, 2.58984375
▁a 1.7958984375
▁type 1.7939453125
▁of 0.0025806427001953125
▁skin 0.1939697265625
▁cancer 0.007633209228515625
, 0.13671875
▁is 0.55859375
▁a 1.9912109375
▁serious 2.072265625
▁health 2.03125
▁concern 1.4228515625
▁that 2.28515625
▁affect 1.2373046875
s 0.0006732940673828125
▁individuals 3.57421875
▁of 0.416259765625
▁all 0.019866943359375
▁ages 0.10308837890625
. 1.0283203125
▁However 4.015625
, 0.00040221214294433594
▁recent 4.15234375
▁adv 3.623046875
anc 0.61083984375
ements 0.00023174285888671875
▁in 0.017303466796875
▁mel 2.212890625
an 0.0004150867462158203
oma 0.0031032562255859375
▁treatment 0.73486328125
▁have 0.3408203125
▁brought 4.46484375
▁hope 1.0107421875
▁to 0.19189453125
▁patients 1.423828125
▁by 4.39453125
▁en 4.38671875
han 1.3271484375
cing 5.960464477539062e-07
▁long 6.94921875
- 0.0152130126953125
term 0.022186279296875
▁rem 3.978515625
ission 0.049041748046875
▁rates 0.438232421875
. 0.7412109375
▁Im 5.453125
m 3.28515625
une 0.1561279296875
▁check 0.3505859375
point 0.004756927490234375
▁in 0.1336669921875
hib 5.805492401123047e-05
itors 0.0819091796875
▁and 3.578125
▁adj 4.87890625
uv 0.011474609375
ant 0.018157958984375
▁ther 0.3740234375
ap 1.1689453125
ies 0.00013363361358642578
▁have 1.453125
▁emer 1.5556640625
ged 0.0001398324966430664
▁as 0.00908660888671875
▁ground 5.35546875
bre 0.2325439453125
aking 5.125999450683594e-06
▁treatment 2.9921875
▁options 0.259033203125
, 1.8154296875
▁revolution 3.013671875
izing 0.00928497314453125
▁the 0.2044677734375
▁landscape 1.6591796875
▁of 0.031768798828125
▁mel 0.08416748046875
an 5.614757537841797e-05
oma 0.00024700164794921875
▁treatment 1.2568359375
▁and 2.099609375
▁impro 1.5625
ving 0.0004978179931640625
▁surv 2.123046875
ival 0.00862884521484375
▁rates 0.314697265625
. 0.275390625
▁This 2.05078125
▁ess 2.9609375
ay 0.0003814697265625
▁will 0.6689453125
▁explore 1.11328125
▁the 0.191650390625
▁imp 5.51171875
lications 0.031036376953125
▁of 0.051483154296875
▁these 0.35400390625
▁treat 2.150390625
ments 3.910064697265625e-05
▁for 2.02734375
▁patients 1.0439453125
▁at 7.22265625
▁different 2.517578125
▁stages 0.0552978515625
▁of 0.041015625
▁mel 0.65966796875
an 6.0677528381347656e-05
oma 0.0005478858947753906
, 1.107421875
▁using 8.53125
▁Mr 9.9765625
. 0.11383056640625
▁B 3.98828125
' 2.17578125
s 0.0013713836669921875
▁case 0.380126953125
▁as 0.310791015625
▁an 1.154296875
▁exempl 2.708984375
ar 0.1182861328125
, 3.142578125
▁alongside 5.3828125
▁research 4.6796875
▁evidence 2.794921875
. 1.3671875
<0x0A> 0.223876953125
Body 7.6328125
: 0.41748046875
<0x0A> 1.52734375
1 3.353515625
. 0.13427734375
▁Im 4.3203125
m 0.1737060546875
une 0.005588531494140625
▁Check 1.91796875
point 0.016937255859375
▁In 0.02130126953125
hib 6.783008575439453e-05
itors 0.031280517578125
: 0.49853515625
<0x0A> 0.35498046875
▁▁ 14.3671875
▁Im 4.640625
m 0.04302978515625
une 0.0006399154663085938
▁check 0.037139892578125
point 0.0042877197265625
▁in 0.0027256011962890625
hib 4.458427429199219e-05
itors 0.0059661865234375
, 2.234375
▁such 0.478515625
▁as 0.00025534629821777344
▁p 1.67578125
emb 0.004390716552734375
rol 0.0004088878631591797
iz 0.000583648681640625
um 0.00063323974609375
ab 0.00022339820861816406
▁and 1.0244140625
▁n 0.380615234375
iv 0.0004839897155761719
ol 0.0010576248168945312
um 0.0012531280517578125
ab 0.00012159347534179688
, 0.01262664794921875
▁work 2.341796875
▁by 0.0240936279296875
▁un 2.2578125
le 0.46826171875
ash 3.218650817871094e-05
ing 2.276897430419922e-05
▁the 0.0390625
▁body 1.8017578125
' 0.023681640625
s 6.35385513305664e-05
▁imm 0.10784912109375
une 0.0008387565612792969
▁system 0.06378173828125
▁to 0.19482421875
▁fight 1.2294921875
▁cancer 0.77783203125
▁cells 0.90771484375
. 0.22412109375
▁These 0.9091796875
▁in 2.904296875
hib 0.0032291412353515625
itors 0.0029296875
▁block 1.29296875
▁prote 3.203125
ins 3.743171691894531e-05
▁that 0.6796875
▁prevent 1.8408203125
▁T 1.869140625
▁cells 0.8349609375
▁from 0.367919921875
▁attack 0.61865234375
ing 5.078315734863281e-05
▁cancer 0.20361328125
▁cells 0.0228271484375
, 0.2376708984375
▁rein 11.4765625
for 0.00597381591796875
cing 0.0011548995971679688
▁the 0.2113037109375
▁imm 0.4755859375
une 0.0032367706298828125
▁response 1.1748046875
▁against 1.3544921875
▁mel 1.10546875
an 3.3020973205566406e-05
oma 0.0029163360595703125
. 0.25927734375
<0x0A> 1.232421875
▁▁ 1.478515625
▁- 4.2421875
▁In 2.46875
▁Mr 1.080078125
. 0.00969696044921875
▁B 0.007488250732421875
' 0.042633056640625
s 0.0002772808074951172
▁case 0.031951904296875
, 0.0297698974609375
▁who 7.4140625
▁was 1.6669921875
▁diagn 0.27734375
osed 7.927417755126953e-05
▁with 0.03179931640625
▁stage 0.85498046875
▁III 1.4814453125
▁mel 0.56787109375
an 0.00010347366333007812
oma 0.00016200542449951172
, 0.2271728515625
▁imm 0.640625
une 0.01471710205078125
▁check 0.004730224609375
point 0.00360870361328125
▁in 0.003650665283203125
hib 1.537799835205078e-05
itors 0.0173187255859375
▁hold 9.1640625
▁the 2.5234375
▁potential 0.268310546875
▁to 0.27001953125
▁enh 2.25390625
ance 4.100799560546875e-05
▁his 1.60546875
▁long 0.56982421875
- 0.001712799072265625
term 0.0013523101806640625
▁rem 0.0948486328125
ission 0.0011119842529296875
▁prospect 5.37109375
s 0.004863739013671875
. 0.3486328125
▁By 3.51171875
▁boost 3.380859375
ing 3.612041473388672e-05
▁his 0.9912109375
▁imm 0.1234130859375
une 0.01277923583984375
▁system 0.34423828125
, 0.45166015625
▁these 0.338134765625
▁in 0.54541015625
hib 0.0011072158813476562
itors 0.00046634674072265625
▁may 1.5576171875
▁target 5.4921875
▁any 2.0546875
▁remaining 0.9306640625
▁cancer 0.28466796875
▁cells 0.0309906005859375
, 1.1259765625
▁reducing 1.54296875
▁the 0.06341552734375
▁ch 3.8984375
ances 0.00011551380157470703
▁of 0.0036296844482421875
▁rec 0.79296875
urrence 0.0168914794921875
. 0.36865234375
<0x0A> 0.1092529296875
▁▁ 1.4521484375
▁- 0.1014404296875
▁A 4.7890625
▁study 1.1142578125
▁by 0.60302734375
▁Long 6.6875
▁et 0.1290283203125
▁al 0.0081939697265625
. 0.05712890625
▁( 0.173828125
2 0.0035762786865234375
0 0.00023221969604492188
1 0.64453125
9 1.26171875
) 0.01708984375
▁demonstrated 1.9814453125
▁that 0.343994140625
▁combining 4.79296875
▁imm 0.671875
une 0.0244903564453125
▁check 0.00580596923828125
point 0.0021724700927734375
▁in 0.01122283935546875
hib 6.9141387939453125e-06
itors 0.0139312744140625
▁with 0.0792236328125
▁standard 3.953125
▁treat 3.662109375
ments 3.337860107421875e-05
▁resulted 3.150390625
▁in 0.0001850128173828125
▁significantly 2.8828125
▁improved 0.72265625
▁surv 1.16015625
ival 0.0003857612609863281
▁rates 0.08795166015625
▁for 0.99755859375
▁patients 0.234130859375
▁with 0.035247802734375
▁stage 1.4599609375
▁III 0.133544921875
▁mel 0.2476806640625
an 2.753734588623047e-05
oma 0.00043392181396484375
, 1.775390625
▁p 6.3203125
aving 0.0205230712890625
▁the 0.0104217529296875
▁way 0.003810882568359375
▁for 0.007518768310546875
▁highly 8.5625
▁prom 2.09765625
ising 0.00011932849884033203
▁th 3.10546875
era 0.00025343894958496094
pe 7.867813110351562e-06
ut 7.152557373046875e-07
ic 0.01001739501953125
▁approaches 1.740234375
. 0.2880859375
<0x0A> 0.0816650390625
2 0.330810546875
. 0.0015850067138671875
▁Ad 0.015350341796875
j 0.001018524169921875
uv 0.0008950233459472656
ant 0.00033354759216308594
▁Ther 0.056884765625
ap 0.273681640625
ies 1.71661376953125e-05
: 0.01068115234375
<0x0A> 0.01255035400390625
▁▁ 0.1754150390625
▁Ad 0.07196044921875
j 8.428096771240234e-05
uv 0.00035762786865234375
ant 0.0005698204040527344
▁ther 0.01079559326171875
ap 0.061065673828125
ies 1.0728836059570312e-06
, 0.3115234375
▁such 0.111083984375
▁as 4.3511390686035156e-05
▁target 2.728515625
ed 0.0032215118408203125
▁ther 0.1607666015625
apy 1.0947265625
▁and 0.401611328125
▁imm 1.537109375
un 0.08233642578125
other 0.001434326171875
apy 0.01018524169921875
, 0.0088958740234375
▁are 0.71337890625
▁admin 2.48828125
ister 0.00011515617370605469
ed 1.5139579772949219e-05
▁after 0.280517578125
▁primary 2.45703125
▁treat 3.001953125
ments 0.00011074542999267578
▁to 0.3671875
▁eliminate 3.45703125
▁any 0.10986328125
▁resid 1.765625
ual 0.0007066726684570312
▁cancer 0.184326171875
▁cells 0.0173492431640625
, 3.224609375
▁lower 3.326171875
ing 0.060028076171875
▁the 0.005023956298828125
▁ch 1.578125
ances 6.556510925292969e-06
▁of 0.0011415481567382812
▁re 2.6015625
lapse 0.0780029296875
. 0.0869140625
<0x0A> 0.281005859375
▁▁ 0.01163482666015625
▁- 0.06658935546875
▁In 0.5947265625
▁advanced 10.1015625
▁mel 0.97412109375
an 2.7179718017578125e-05
oma 0.0158538818359375
▁cases 0.892578125
, 0.198974609375
▁combining 6.15234375
▁adj 0.36083984375
uv 0.0014190673828125
ant 0.003086090087890625
▁ther 0.0635986328125
ap 0.0574951171875
ies 9.775161743164062e-06
▁with 0.09942626953125
▁imm 0.402587890625
une 0.18603515625
▁check 0.006229400634765625
point 0.002323150634765625
▁in 0.001682281494140625
hib 7.3909759521484375e-06
itors 0.004749298095703125
▁has 2.029296875
▁been 1.58203125
▁found 1.2998046875
▁to 0.0227508544921875
▁be 1.4541015625
▁particularly 2.46484375
▁effective 0.2073974609375
. 0.77099609375
▁Assuming 13.25
▁Mr 0.59130859375
. 0.0031261444091796875
▁B 0.00341796875
▁progress 4.09375
es 0.326904296875
▁to 0.1156005859375
▁stage 0.487548828125
▁IV 0.036590576171875
▁mel 0.303955078125
an 0.00011670589447021484
oma 3.2067298889160156e-05
, 0.0687255859375
▁this 3.265625
▁combination 0.828125
▁may 1.0126953125
▁offer 2.880859375
▁further 5.15625
▁hope 2.09765625
▁for 0.43310546875
▁long 0.63916015625
- 0.0014181137084960938
term 0.01294708251953125
▁rem 0.038238525390625
ission 0.0015716552734375
▁by 3.328125
▁not 8.640625
▁only 0.2301025390625
▁elimin 1.9287109375
ating 5.8770179748535156e-05
▁remaining 2.44140625
▁cancer 0.09271240234375
▁cells 0.00867462158203125
▁but 0.049774169921875
▁also 0.03460693359375
▁hal 8.1484375
ting 0.00044274330139160156
▁the 1.158203125
▁spread 1.4775390625
▁of 0.04754638671875
▁the 0.68603515625
▁disease 0.05419921875
. 0.126953125
<0x0A> 0.01226043701171875
▁▁ 0.1708984375
▁- 0.060333251953125
▁Research 3.1015625
▁conducted 3.169921875
▁by 0.0238189697265625
▁Hass 7.1640625
el 1.23828125
▁et 0.1697998046875
▁al 0.0009160041809082031
. 0.0030498504638671875
▁( 0.0008797645568847656
2 0.0003712177276611328
0 1.0728836059570312e-06
1 0.67041015625
9 0.8291015625
) 0.00604248046875
▁demonstrated 1.9931640625
▁that 0.1380615234375
▁the 2.01171875
▁use 2.09375
▁of 0.00017321109771728516
▁adj 0.28955078125
uv 0.002246856689453125
ant 0.0011472702026367188
▁imm 2.58203125
un 0.1776123046875
other 0.001651763916015625
apy 0.06866455078125
▁post 5.109375
- 0.09649658203125
s 0.396728515625
urg 0.0004029273986816406
ical 2.072265625
▁res 0.72705078125
ection 0.0022945404052734375
▁significantly 2.47265625
▁impro 4.27734375
ves 7.534027099609375e-05
▁surv 1.1435546875
ival 0.00077056884765625
▁rates 0.1285400390625
▁and 3.359375
▁reduces 0.7177734375
▁the 0.313232421875
▁risk 0.4560546875
▁of 0.0005927085876464844
▁re 1.3037109375
lapse 0.01806640625
▁in 0.6416015625
▁high 4.21484375
- 0.0014600753784179688
ris 0.0021190643310546875
k 3.731250762939453e-05
▁stage 1.7080078125
▁III 0.33056640625
▁mel 0.08587646484375
an 1.7762184143066406e-05
oma 0.005779266357421875
▁patients 0.299072265625
. 0.1890869140625
<0x0A> 0.14599609375
Con 1.12109375
clusion 0.00632476806640625
: 0.0185089111328125
<0x0A> 0.1055908203125
The 2.43359375
▁adv 1.6337890625
anc 0.1080322265625
ements 5.3763389587402344e-05
▁in 0.035858154296875
▁mel 0.11248779296875
an 3.981590270996094e-05
oma 1.5497207641601562e-05
▁treatment 0.054962158203125
, 1.4677734375
▁primarily 4.96875
▁through 1.53125
▁imm 0.373046875
une 0.02838134765625
▁check 0.0015583038330078125
point 0.002105712890625
▁in 0.00118255615234375
hib 1.430511474609375e-06
itors 0.00433349609375
▁and 0.01220703125
▁adj 0.002887725830078125
uv 0.0004317760467529297
ant 0.0005159378051757812
▁ther 0.0032825469970703125
ap 0.002124786376953125
ies 5.4836273193359375e-06
, 0.005512237548828125
▁have 0.56640625
▁revolution 1.615234375
ized 0.0036258697509765625
▁the 0.07366943359375
▁prospect 4.39453125
s 0.020477294921875
▁for 0.55029296875
▁long 0.51611328125
- 0.0007996559143066406
term 0.0010051727294921875
▁rem 0.0153350830078125
ission 0.002429962158203125
, 3.47265625
▁ign 9.078125
iting 0.00860595703125
▁hope 0.295654296875
▁for 0.1298828125
▁patients 0.259033203125
▁at 1.8564453125
▁all 0.90625
▁stages 0.01502227783203125
▁of 0.129638671875
▁mel 0.81494140625
an 4.875659942626953e-05
oma 0.00010836124420166016
. 0.06549072265625
▁By 2.521484375
▁target 2.689453125
ing 0.0001323223114013672
▁the 1.5234375
▁imm 0.62060546875
une 0.0011587142944335938
▁system 0.0175323486328125
▁to 3.119140625
▁combat 1.814453125
▁cancer 0.1064453125
▁cells 0.2196044921875
▁and 0.794921875
▁admin 5.2890625
ister 3.635883331298828e-05
▁post 7.9140625
- 0.004852294921875
s 0.595703125
urg 2.2411346435546875e-05
ery 3.16796875
▁treat 0.90625
ments 2.7060508728027344e-05
, 1.515625
▁these 1.2021484375
▁innov 2.025390625
ative 0.5107421875
▁ther 0.84375
ap 0.0012960433959960938
ies 8.940696716308594e-06
▁hold 2.478515625
▁trem 3.056640625
end 1.9073486328125e-06
ous 0.00011610984802246094
▁potential 0.341064453125
▁for 0.9873046875
▁en 1.556640625
han 0.06866455078125
cing 2.753734588623047e-05
▁surv 0.88818359375
ival 0.00585174560546875
▁rates 0.036956787109375
. 2.650390625
<0x0A> 1.9013671875
In 2.33203125
▁Mr 0.9365234375
. 0.0012025833129882812
▁B 0.0013055801391601562
' 0.0117950439453125
s 9.143352508544922e-05
▁case 0.058990478515625
, 0.018096923828125
▁the 1.4521484375
▁jud 9.40625
icious 0.0227203369140625
▁util 3.908203125
ization 0.002323150634765625
▁of 0.0005745887756347656
▁imm 1.3046875
une 0.019622802734375
▁check 0.005016326904296875
point 0.0020923614501953125
▁in 0.0016651153564453125
hib 4.172325134277344e-06
itors 0.003124237060546875
▁and 0.310302734375
▁adj 0.028289794921875
uv 0.0010509490966796875
ant 0.0007395744323730469
▁ther 0.02789306640625
ap 0.00540924072265625
ies 1.430511474609375e-06
▁could 2.26171875
▁significantly 1.3662109375
▁improve 0.59521484375
▁his 0.052886962890625
▁ch 1.6328125
ances 3.6954879760742188e-06
▁of 0.09295654296875
▁ach 2.349609375
ieving 1.3470649719238281e-05
▁a 3.11328125
▁long 0.2137451171875
- 0.00911712646484375
term 0.041473388671875
▁rem 0.0161285400390625
ission 5.030632019042969e-05
. 0.9658203125
▁Furthermore 4.2578125
, 7.76052474975586e-05
▁research 2.578125
▁evidence 0.6328125
▁supports 1.49609375
▁the 0.248291015625
▁consistent 9.4765625
▁positive 3.416015625
▁out 1.28515625
comes 0.00386810302734375
▁observed 4.74609375
, 4.859375
▁suggesting 3.845703125
▁that 0.2186279296875
▁these 0.45166015625
▁treat 0.81298828125
ments 2.3365020751953125e-05
▁may 1.3544921875
▁become 2.7421875
▁standard 2.470703125
▁practice 1.1416015625
▁for 0.8671875
▁mel 1.0703125
an 1.1324882507324219e-05
oma 0.00012564659118652344
▁treatment 3.0703125
▁across 5.98046875
▁the 1.326171875
▁medical 3.5234375
▁community 0.97509765625
. 0.11248779296875
<0x0A> 0.5439453125
As 3.33203125
▁we 1.970703125
▁continue 1.16796875
▁to 0.025970458984375
▁expand 4.51953125
▁our 0.08074951171875
▁understanding 0.68359375
▁of 0.0290374755859375
▁the 1.7001953125
▁imm 2.318359375
une 0.032958984375
▁system 0.0165863037109375
' 1.732421875
s 5.817413330078125e-05
▁role 0.75830078125
▁in 0.0012960433959960938
▁fighting 1.396484375
▁cancer 0.1175537109375
, 0.1217041015625
▁it 1.4560546875
▁is 0.1434326171875
▁evident 2.447265625
▁that 0.0010690689086914062
▁imm 1.1796875
une 0.141357421875
▁check 0.009429931640625
point 0.0019741058349609375
▁in 0.0015039443969726562
hib 9.5367431640625e-07
itors 0.003589630126953125
▁and 0.03564453125
▁adj 0.00534820556640625
uv 0.0012788772583007812
ant 0.0005650520324707031
▁ther 0.00957489013671875
ap 0.000759124755859375
ies 3.933906555175781e-06
▁are 1.716796875
▁the 2.8125
▁pill 7.9296875
ars 0.00994110107421875
▁of 0.1453857421875
▁hope 3.08984375
, 5.18359375
▁prom 3.884765625
ising 0.367431640625
▁a 1.39453125
▁br 0.326171875
ighter 1.6689300537109375e-05
▁future 0.06390380859375
▁for 0.01824951171875
▁mel 1.4375
an 1.2874603271484375e-05
oma 3.3736228942871094e-05
▁patients 0.04913330078125
. 0.552734375
▁By 3.40625
▁invest 3.583984375
ing 0.00010180473327636719
▁in 0.0313720703125
▁on 3.958984375
going 0.0021839141845703125
▁research 0.052276611328125
▁and 0.2012939453125
▁clin 2.416015625
ical 0.00037860870361328125
▁tri 0.0303802490234375
als 2.9802322387695312e-06
, 0.1002197265625
▁we 0.11370849609375
▁can 0.0908203125
▁push 5.2578125
▁the 0.1829833984375
▁boundaries 0.10772705078125
▁of 0.0204925537109375
▁medical 2.025390625
▁innov 1.337890625
ation 0.013336181640625
, 1.26171875
▁potentially 4.5078125
▁transform 1.9736328125
ing 0.0004987716674804688
▁mel 1.8115234375
an 1.800060272216797e-05
oma 6.592273712158203e-05
▁from 2.15625
▁a 0.0279388427734375
▁h 8.125
arrow 0.022003173828125
ing 0.0007839202880859375
▁diagn 0.62353515625
osis 0.0002276897430419922
▁to 0.38330078125
▁a 0.0297393798828125
▁manage 0.418701171875
able 6.556510925292969e-06
▁disease 1.7333984375
. 0.1270751953125
